Kusajili – Clinical trials directory

Result of your search per sponsor: Thallion Pharmaceutiques Inc.

Woman and Man
Between 18 years
and 99 years
Thallion Pharmaceutiques Inc. Update Il y a 4 ans

Thallion CTP_CAP001 : Essai de phase 2 évaluant l’efficacité et la tolérance du CAP-232 chez des patients ayant un cancer du rein. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] A multi-centre, open label, phase II study of the safety, efficacy and pharmacokinetic (PK) profile of CAP-232 administered through continuous intravenous infusion in patients with metastatic kidney c...

Country France
organs Rein
Specialty Chimiothérapie

Essai clos aux inclusions

More information